Recasts paragraph 1 to add valuation
June 16 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.
The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
Caris will start trading on the Nasdaq on Wednesday under the symbol 'CAI'.
(Reporting by Arasu Kannagi Basil and Pritam Biswas in Bengaluru; Editing by Shreya Biswas)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。